What changed
$REGN — HOLD 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.6B | EPS $9.47 vs $8.90 🟢 | Margin 17.8%
💡 Consensus underestimated quarterly earnings by ~6.4%, but the beat is now public. Market-implied expectations have likely adjusted; near-term earnings upgrade potential is mostly priced in, leaving little variant view.
📉 Reward/risk: 1.0:1
🏢 Business Quality: 8/10 - diversified biologics portfolio, durable Dupixent franchise, and credible pipeline offset by Eylea biosimilar overhang
📊 Valuation: fair – PE 14.9x is slightly above its own narrow historical range (14.7–14.9x, median 14.8x), and roughly in line with large-cap biotech peers;...
🔮 Catalyst: Q1 2026 earnings report (31-Mar-2026) – already occurred
💰 Entry: $610, stop $580, target $640
📊 Our read: HOLD. Full analysis →
https://stockduty.xyz/s/REGN0621